Free Trial

Longeveron (LGVN) Competitors

Longeveron logo
$0.83 -0.01 (-1.22%)
Closing price 10/22/2025 04:00 PM Eastern
Extended Trading
$0.82 -0.01 (-1.68%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LGVN vs. STRO, RLMD, DTIL, INKT, NRXP, ICCC, CUE, GNTA, ALGS, and ANL

Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Sutro Biopharma (STRO), Relmada Therapeutics (RLMD), Precision BioSciences (DTIL), MiNK Therapeutics (INKT), NRx Pharmaceuticals (NRXP), ImmuCell (ICCC), Cue Biopharma (CUE), Genenta Science (GNTA), Aligos Therapeutics (ALGS), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry.

Longeveron vs. Its Competitors

Longeveron (NASDAQ:LGVN) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Sutro Biopharma has a net margin of -201.32% compared to Longeveron's net margin of -894.40%. Longeveron's return on equity of -95.91% beat Sutro Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Longeveron-894.40% -95.91% -79.69%
Sutro Biopharma -201.32%-852.70%-58.67%

Longeveron has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longeveron$2.39M7.30-$15.97M-$6.28-0.13
Sutro Biopharma$62.04M1.58-$227.46M-$2.53-0.46

10.0% of Longeveron shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Longeveron has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Longeveron currently has a consensus price target of $7.67, indicating a potential upside of 824.92%. Sutro Biopharma has a consensus price target of $4.47, indicating a potential upside of 285.06%. Given Longeveron's stronger consensus rating and higher probable upside, equities research analysts plainly believe Longeveron is more favorable than Sutro Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Longeveron
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Sutro Biopharma
2 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Sutro Biopharma had 10 more articles in the media than Longeveron. MarketBeat recorded 11 mentions for Sutro Biopharma and 1 mentions for Longeveron. Sutro Biopharma's average media sentiment score of 1.44 beat Longeveron's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Longeveron
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Sutro Biopharma
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Longeveron and Sutro Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LGVN vs. The Competition

MetricLongeveronMED IndustryMedical SectorNASDAQ Exchange
Market Cap$17.67M$3.47B$6.16B$10.67B
Dividend YieldN/A2.24%5.72%4.86%
P/E Ratio-0.1322.9129.0927.13
Price / Sales7.30463.56571.59126.20
Price / CashN/A45.5937.1261.42
Price / Book0.5610.2912.206.43
Net Income-$15.97M-$52.53M$3.33B$276.63M
7 Day Performance0.17%-0.60%-0.78%-0.77%
1 Month Performance6.68%10.30%5.28%0.68%
1 Year Performance-62.66%13.51%68.39%32.03%

Longeveron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
2.1176 of 5 stars
$0.83
-1.2%
$7.67
+824.9%
-59.6%$17.67M$2.39M-0.1320News Coverage
STRO
Sutro Biopharma
4.3195 of 5 stars
$0.83
+3.1%
$4.47
+439.2%
-67.1%$68.13M$62.04M-0.33240Positive News
Gap Down
RLMD
Relmada Therapeutics
2.169 of 5 stars
$2.02
-1.0%
$1.00
-50.5%
-41.2%$67.71MN/A-0.9110
DTIL
Precision BioSciences
3.9017 of 5 stars
$5.56
-1.1%
$47.00
+745.3%
-21.1%$66.24M$68.70M-0.63200Positive News
INKT
MiNK Therapeutics
2.7058 of 5 stars
$14.09
+0.6%
$37.50
+166.1%
+95.1%$63.32MN/A-4.8930Positive News
Analyst Upgrade
NRXP
NRx Pharmaceuticals
2.7501 of 5 stars
$3.12
-1.6%
$34.50
+1,005.8%
+162.5%$62.80MN/A-1.392Analyst Forecast
ICCC
ImmuCell
0.5807 of 5 stars
$6.58
-3.2%
N/A+72.9%$61.51M$26.49M34.6370Gap Up
CUE
Cue Biopharma
2.2559 of 5 stars
$0.82
+2.5%
N/A-52.2%$61.13M$9.29M-1.4660
GNTA
Genenta Science
N/A$3.47
+6.8%
N/A-34.8%$59.44MN/A0.007Gap Down
High Trading Volume
ALGS
Aligos Therapeutics
3.9105 of 5 stars
$9.47
+0.4%
$50.00
+428.0%
+34.1%$58.01M$3.94M-0.4890Gap Down
High Trading Volume
ANL
Adlai Nortye
1.1187 of 5 stars
$1.64
+4.1%
$9.00
+450.5%
-21.4%$57.93M$5M0.00127News Coverage
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:LGVN) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners